Skip to main content
Top
Published in: Rheumatology International 2/2007

01-12-2007 | Case Report

Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjögren’s syndrome

Authors: Pascal Sève, Emilie Gachon, Philippe Petiot, Katia Stankovic, Annick Charhon, Christiane Broussolle

Published in: Rheumatology International | Issue 2/2007

Login to get access

Abstract

We present the case of a 79-year-old female patient with chronic obstructive pulmonary disease on home oxygen therapy who was diagnosed as having Sjögren’s syndrome with arthralgias and painful sensory neuropathy. She subsequently developed bilateral numb chin syndrome. Because of refractory and disabling symptoms under high corticosteroids and severe chronic obstructive pulmonary disease, we decided to treat her with rituximab rather than immunosuppressants. This resulted in significant subjective improvement in sicca syndrome while arthalgias, distal and chin paresthesias resolved completely. To our knowledge this is the first description of such a case.
Literature
1.
go back to reference Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 61:554–558PubMedCrossRef Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 61:554–558PubMedCrossRef
2.
go back to reference Bell C (1829): On the nerves of the face: being a second paper on that subject. Philos Trans R Soc Lond 119:317–330CrossRef Bell C (1829): On the nerves of the face: being a second paper on that subject. Philos Trans R Soc Lond 119:317–330CrossRef
3.
go back to reference Roger H, Paillas J (1937) Le signe du mentonnier (paresthésie et anesthésie unilatérale) révélateur d’un processus néoplasique. Rev Neurol 2:751–752 Roger H, Paillas J (1937) Le signe du mentonnier (paresthésie et anesthésie unilatérale) révélateur d’un processus néoplasique. Rev Neurol 2:751–752
4.
go back to reference Sweet JM (2004) The numb chin syndrome: a critical sign for primary care physicians. Arch Intern Med 164:1347–1348PubMedCrossRef Sweet JM (2004) The numb chin syndrome: a critical sign for primary care physicians. Arch Intern Med 164:1347–1348PubMedCrossRef
5.
go back to reference Abilleira S, Bowler JV (2005) The numb chin syndrome as an early manifestation of giant-cell (temporal) arteritis: a case report. Headache 45:1411–1413PubMedCrossRef Abilleira S, Bowler JV (2005) The numb chin syndrome as an early manifestation of giant-cell (temporal) arteritis: a case report. Headache 45:1411–1413PubMedCrossRef
6.
go back to reference Ashworth B, Tait GB (1971) Trigeminal neuropathy in connective tissue disease. Neurology 21:609–614PubMed Ashworth B, Tait GB (1971) Trigeminal neuropathy in connective tissue disease. Neurology 21:609–614PubMed
7.
go back to reference Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, Dubucquoi S, Pruvo JP, Vermersch P, Hatron PY (2004) Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 83:280–291CrossRef Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, Dubucquoi S, Pruvo JP, Vermersch P, Hatron PY (2004) Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 83:280–291CrossRef
8.
go back to reference Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, Katsuno M, Fujita A, Aiba I, Ogata A, Saito T, Asakura K, Yoshida M, Hirayama M, Sobue G (2005) The wide spectrum of clinical manifestations in Sjogren’s syndrome-associated neuropathy. Brain 128:2518–2534PubMedCrossRef Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, Katsuno M, Fujita A, Aiba I, Ogata A, Saito T, Asakura K, Yoshida M, Hirayama M, Sobue G (2005) The wide spectrum of clinical manifestations in Sjogren’s syndrome-associated neuropathy. Brain 128:2518–2534PubMedCrossRef
9.
go back to reference Isenberg D (2006) B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 77:24–28PubMed Isenberg D (2006) B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 77:24–28PubMed
10.
go back to reference Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H (2005) Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum 52:2740–2750PubMedCrossRef Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H (2005) Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum 52:2740–2750PubMedCrossRef
11.
go back to reference Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Leguern V, Aouba A, Jean S, Gottenberg JE, Mariette X (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren’s syndrome. Ann Rheum Dis 66:351–357PubMedCrossRef Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Leguern V, Aouba A, Jean S, Gottenberg JE, Mariette X (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren’s syndrome. Ann Rheum Dis 66:351–357PubMedCrossRef
12.
go back to reference Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL (2005) Successful treatment of refractory anterior scleritis in primary Sjogren’s syndrome with rituximab. Ann Rheum Dis 64:1087–1088PubMedCrossRef Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL (2005) Successful treatment of refractory anterior scleritis in primary Sjogren’s syndrome with rituximab. Ann Rheum Dis 64:1087–1088PubMedCrossRef
13.
go back to reference Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B (2006) Successful treatment of a patient with primary Sjogren’s syndrome with Rituximab. Clin Rheumatol 25:891–894PubMedCrossRef Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B (2006) Successful treatment of a patient with primary Sjogren’s syndrome with Rituximab. Clin Rheumatol 25:891–894PubMedCrossRef
14.
go back to reference Gorson KC, Natarajan N, Ropper AH, Weinstein R (2006) Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 35:66–69CrossRef Gorson KC, Natarajan N, Ropper AH, Weinstein R (2006) Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 35:66–69CrossRef
Metadata
Title
Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjögren’s syndrome
Authors
Pascal Sève
Emilie Gachon
Philippe Petiot
Katia Stankovic
Annick Charhon
Christiane Broussolle
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0396-4

Other articles of this Issue 2/2007

Rheumatology International 2/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.